AC Immune SA (ACIU) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vogenx is the larger company by market cap ($272.6 million vs $252.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | VOGX |
|---|---|---|
| Share price | $2.54 | $18.35 |
| Market cap | $252.05M | $272.59M |
| 1-day change | -0.59% | +4.92% |
| YTD return | -18.79% | — |
| 1-year return | -27.56% | — |
| 5-year return | -58.74% | — |
| Forward P/E | 4.26 | — |
| EPS (TTM) | $-0.54 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $38.41 |
| 52-week low | $2.10 | $12.95 |
| Distance from 52-week high | -36.63% | -52.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +236.09% | +199.73% |
| Average volume | 201.86K | 187.66K |
| Shares outstanding | 99.43M | 14.86M |
| Employees | 90 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ACIU vs VOGX FAQ
Which is bigger, AC Immune SA or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $272.59M compared with $252.05M for AC Immune SA (ACIU).
Are AC Immune SA and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.